The life sciences venture capital company Asabys Partners, member of CATALONIA.HEALTH, announces the investment in the biotech company Agomab Therapeutics, in a Series D funding round that reaches $89 million, along with other existing investors, and with Sanofi and Invius, which join as new investors. Asabys became a shareholder of Agomab in 2021 after Agomab’s acquisition of Origo Biopharma, a company in which Asabys had invested in 2020.
The D-series revenues will be used to further advance the clinical development of Agomab’s lead candidate AGMB-129, an oral inhibitor with activity restricted to the intestine for patients with fibrostatic Crohn disease. Also, to advance the clinical development of AGMB-447, an oral inhibitor with lung-restricted activity, which is currently in a Phase 1 clinical trial in healthy volunteers and in patients with idiopathic pulmonary fibrosis. And, finally, for the initial clinical development of AGMB-101, which the company intends to develop for liver cirrhosis.
Comments